[{"id":"8f688b25-930e-42ca-9a40-fca5c6f5662a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04890236","created_at":"2021-05-18T12:01:56.234Z","updated_at":"2025-02-25T15:54:04.644Z","phase":"Phase 1","brief_title":"Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study","source_id_and_acronym":"NCT04890236","lead_sponsor":"Emory University","biomarkers":" CD27","pipe":"","alterations":" ","tags":["CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • Kymriah (tisagenlecleucel-T) • ETP-47187"],"overall_status":"Completed","enrollment":" Enrollment 4","initiation":"Initiation: 01/13/2022","start_date":" 01/13/2022","primary_txt":" Primary completion: 03/20/2024","primary_completion_date":" 03/20/2024","study_txt":" Completion: 09/04/2024","study_completion_date":" 09/04/2024","last_update_posted":"2025-01-20"},{"id":"8daa166e-7414-41bf-92cd-493c1f6c451c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03961672","created_at":"2021-01-18T19:29:37.641Z","updated_at":"2024-07-02T16:35:19.292Z","phase":"Phase 2","brief_title":"Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT03961672","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2 • CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression","tags":["BCL2 • CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Copiktra (duvelisib) • ETP-47187"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 05/13/2020","start_date":" 05/13/2020","primary_txt":" Primary completion: 06/27/2024","primary_completion_date":" 06/27/2024","study_txt":" Completion: 06/27/2024","study_completion_date":" 06/27/2024","last_update_posted":"2024-02-15"}]